Gramax

Quick links to important sections

Gramax

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gramax

Property Description
Active ingredient Sildenafil Citrate (Sildenafil)
Form Film-coated tablet (Oral)
Pharmacological class Phosphodiesterase Type 5 (PDE5) Inhibitor
General purpose To enhance localized blood flow
Origin Synthetic chemical compound

Gramax is a prescription-only medicine defined by its active component, Sildenafil Citrate, a synthetic substance belonging to the distinct pharmacological category of Phosphodiesterase Type 5 (PDE5) Inhibitors. The drug's fundamental purpose is to support physiological processes that require increased circulation, which is a mechanism clinically recognized for addressing vascular challenges in specific body systems.


Defining Gramax and Its Composition

Gramax is formulated as a single-ingredient product, containing only Sildenafil Citrate as its therapeutic agent, distinguishing it from combination medicines. It is prepared as a film-coated tablet designed for safe oral administration. The active component is a synthetic chemical substance, ensuring precise and consistent concentration in every dose. The medicine is primarily positioned for adult patients seeking support for circulatory-based function. The use of Sildenafil in its citrate salt form is a pharmacological standard aimed at optimizing the drug's stability and bioavailability.

Pharmacological Classification and General Purpose

The drug’s classification as a PDE5 Inhibitor means its action is characterized by the selective blockade of the Phosphodiesterase Type 5 enzyme in specific tissues. This mechanism sustains the duration of the natural signaling molecule cGMP (Cyclic Guanosine Monophosphate), which is responsible for mediating smooth muscle relaxation. Sildenafil's effect is to promote vasodilation, facilitating enhanced blood flow to targeted vascular beds. This action is crucial because it generally helps to relieve symptoms related to insufficient circulation necessary for a proper physiological response, such as in cases involving inadequate blood flow to certain reproductive or pulmonary tissues.

Regulatory References

  1. MedlinePlus Drug Information: Sildenafil

What side effects are possible with Gramax?

Possible Side Effects and Safety Information

The safety profile of Gramax, which contains Sildenafil Citrate, is organized by regulatory agencies using frequency categories and the specific body systems affected. This framework helps distinguish between common, expected effects and rare, serious adverse reactions.

Frequency-Classified Adverse Reactions

The most frequently documented reactions from clinical data are classified as Very Common (ge 1/10) and Common (ge 1/100 to < 1/10).

Classification Common Adverse Reactions
Very Common Headache
Common Flushing, Dizziness, Dyspepsia, Nasal Congestion, Abnormal Vision (e.g., color tinge, blurred vision), Back Pain, Myalgia, Nausea

These effects are typically classified under Nervous System Disorders, Vascular Disorders, Gastrointestinal Disorders, and Eye Disorders in official labeling.


Serious Adverse Reactions and Safety Constraints

The label documents rare but clinically significant adverse reactions that have been reported in temporal association with Sildenafil use. These include Priapism (a prolonged erection lasting four hours or longer), sudden visual loss due to Non-arteritic Anterior Ischemic Optic Neuropathy (NAION), and sudden hearing loss. These serious effects require immediate cessation of the medicine, as officially noted.

Specific safety constraints are mandated in the regulatory documents. The medicine is strictly contraindicated for co-administration with any organic nitrates or nitric oxide donors due to the risk of severe, life-threatening hypotension. Furthermore, use is generally contraindicated in patients with severe hepatic impairment or specific recent cardiovascular events, such as a myocardial infarction or stroke within the last six months.

Overdose and Emergency Response

Overdose and Acute Exposure Risk

The primary health concern following accidental exposure to Gramax, a product containing microbial components, is the potential for sensitisation or allergic reaction, mainly through inhalation. While the mixture is generally described as non-toxic in acute testing, excessive exposure may cause respiratory symptoms.

Symptoms and Affected Systems

Symptoms associated with inhalation may include breathing difficulties or shortness of breath. The product contains microorganisms that are categorized in hazard group 1, and individuals who are immunocompromised should avoid handling the product to minimize the risk of infection.

Emergency Action and When to Seek Medical Help

In case of inhalation: Move the exposed person to fresh air. If breathing becomes difficult or stops (respiratory failure), administer artificial respiration and seek immediate medical attention.

Exposure Route Required First Aid Instruction
Inhalation (Aerosol/Dust) Move to fresh air, keep quiet and warm. Seek medical attention for respiratory failure.
Skin Contact Wash affected areas thoroughly with plenty of water.
Eye Contact Remove contact lenses (if applicable). Rinse eyes with water for at least 15 minutes while holding eyelids apart.
Ingestion Rinse mouth with water and drink plenty of water. Do not induce vomiting.

Immediate medical help is required if the exposed individual experiences signs of respiratory failure following aspiration or inhalation. Consult safety information for comprehensive first-aid guidance for all exposure incidents.

Therapeutic Uses of Gramax

What Gramax Treats: Main Uses and Benefits

Gramax is commonly used in therapeutic domains where supportive management is appropriate. The medication is applied in situations involving certain distressing symptoms and helps maintain a sense of stability when symptoms are more noticeable. It is applied across conditions presenting with localized discomfort, chiefly addressing Erectile Dysfunction (ED) and the symptomatic burden of Pulmonary Arterial Hypertension (PAH).


Supporting Functional Stability

This therapeutic domain is relevant for managing symptom clusters that may become disruptive, such as the difficulty in achieving or maintaining an adequate erection for sexual activity, or reduced exercise ability associated with PAH. The medication supports the patient by assisting with functional stability, which helps improve day-to-day comfort and ease the overall symptom load.

Quick Fact: Support for Functional Strain Gramax may assist with maintaining functional stability across its primary domains of use.


Managing Symptom Burden

Gramax is applied in addressing the symptoms linked to Pulmonary Arterial Hypertension (PAH), a condition marked by increased physiological stress, such as shortness of breath. It is used across domains where additional symptomatic support is needed. This therapeutic use contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus overview of Sildenafil

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Gramax?

The official eligibility for Gramax (Sildenafil Citrate) is strictly defined by regulatory authorities and centers on absolute contraindications and population-specific risk.

Eligibility Scope Status Regulatory Basis
Adults (18 years and older) Allowed Indicated population.
Pediatric Population Not Indicated Use for ED is not indicated. Use for PAH is generally not recommended below 18 years.
Pregnancy/Lactation Not Established Not indicated for women (ED). Safety in breastfeeding is unknown.

Contraindicated Populations

Gramax must not be used by patients taking Organic Nitrates (any form) or Guanylate Cyclase Stimulators (e.g., riociguat) due to the risk of severe hypotension. Contraindication also applies to those with Known Hypersensitivity to sildenafil, a recent history of stroke or myocardial infarction (within 6 months), severe cardiac failure, severe hepatic impairment, or resting hypotension (BP < 90/50 mmHg).

Eligibility-Related Restrictions

Use requires caution in patients with severe renal impairment, mild-to-moderate hepatic impairment, or those taking Alpha-Blockers. Caution is also needed for individuals with conditions predisposing to Priapism (e.g., sickle cell anemia) or a history of Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION). Use is not recommended in patients with Pulmonary Veno-Occlusive Disease (PVOD).

What should I know about interactions with other medicines?

Gramax Interactions with other medicines and products

Interaction Scope

The officially documented interaction profile for Gramax primarily involves restrictions related to timing and concurrent drug use. Interactions are generally classified based on their potential to alter the effects of Gramax or increase the risk of adverse physiological outcomes.

Medicinal product categories with documented interactions:

  • Myelosuppressive Chemotherapy Agents: Agents that suppress bone marrow function.
  • Other Hematopoietic Growth Factors: Other filgrastim or pegfilgrastim products.

Specific interacting medicines (if explicitly listed): None are individually listed; only product classes are specified.

Mechanistic basis of interactions (only if stated in label): Anticipated myelosuppression and Additive pharmacological effect on the G-CSF receptor system.

Timing-based interaction rules (if applicable):

  • Do not administer Gramax in the period 24 hours before and 24 hours after administration of chemotherapy.

Population-specific interaction notes (if applicable): None specifically documented in the interaction section.

Interaction-related restrictions:

  • Use of Gramax is contraindicated simultaneously with other filgrastim or pegfilgrastim products.

Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents): Avoid/Contraindicated (for concurrent use with myelosuppressive chemotherapy and other G-CSF products).

Regulatory basis: US Food and Drug Administration (FDA) and/or European Medicines Agency (EMA) standards for hematopoietic growth factors.

Interaction-context constraints (as defined in official documents):

  • Must be administered outside of the perichemotherapy window.

Resulting Interaction Structure

Official interaction statements:

  • Administration of Gramax concurrently with myelosuppressive chemotherapy agents is restricted due to the potential for interaction with the rapidly dividing myeloid cells.
  • Co-administration of Gramax with any other filgrastim or pegfilgrastim product is prohibited because of the overlapping pharmacological actions on the hematopoietic system.

Connection to the overall interaction profile (2–4 sentences): Regulatory documentation defines Gramax's interaction profile through a critical temporal constraint regarding chemotherapy and a definitive restriction against simultaneous use with similar growth factors. This structure ensures that the drug is only used in a manner that maximizes its intended effect on neutrophil production without interfering with the action of cytotoxic agents or risking an additive effect from related medicines.

Mechanism of Action

The mechanism of action of Gramax (Sildenafil) is defined by its selective influence over a core vascular signaling pathway, resulting in localized vasodilation and reduced vascular resistance.


Selective Inhibition of the PDE5 Enzyme

This domain describes the primary molecular target: Sildenafil acts as a selective competitive inhibitor of the Phosphodiesterase Type 5 (PDE5) enzyme, preventing the breakdown of the signaling molecule cGMP (Cyclic Guanosine Monophosphate). This enzymatic blockade results in the prolongation of the chemical signal for relaxation within the smooth muscle cells of the target vasculature.


Potentiation of the Nitric Oxide-cGMP Pathway

Gramax does not initiate a new signal; instead, it amplifies the effect of the body's natural response by potentiating the Nitric Oxide (NO)-cGMP signaling cascade. By stabilizing cGMP levels, the drug extends the influence of endogenous NO release, leading to a more pronounced downstream physiological effect.


Regulation of Localized Vascular Tone

The sustained high levels of cGMP directly trigger a cascade that leads to a reduction in intracellular calcium, causing the target vascular smooth muscle to reduce its contractile state. This reduction in contractile state leads to localized vasodilation, resulting in reduced vascular resistance within the targeted tissues.

Dosage and Administration Information

How Gramax is Used: General Administration Guidelines

Gramax (Sildenafil Citrate) is administered according to two distinct procedural patterns based on its indication, ensuring the correct route, dose, and frequency are utilized. The medication is available as oral film-coated tablets and, for specific scenarios, as a solution for intravenous (IV) injection.

Administration Schedule and Dosing

Indication Standard Dose Range Frequency and Timing
Erectile Dysfunction (ED) 25 mg to 100 mg (Max 100 mg/day) Taken as needed, up to once daily, typically 30 minutes to 4 hours before activity.
Pulmonary Arterial Hypertension (PAH) 20 mg (Oral) or 10 mg (IV) Administered on a fixed schedule, typically three times a day (TID), with doses separated by 4 to 6 hours.

Administration is generally flexible concerning meals, as the dose can be taken with or without food. However, it is noted that consuming a high-fat meal may delay the time until the effect is observed. For certain populations, it is suggested to initiate treatment with a lower dose; for instance, a starting dose of 25 mg is considered for older adults (over 65 years) and patients with severe hepatic or renal impairment when treating the ED indication.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gramax

This overview describes the scope of clinical research conducted on Gramax (Sildenafil Citrate), focusing on the types of studies available for its approved uses, the outcomes that were monitored, and areas where evidence remains limited or uncertain. This information is derived exclusively from official regulatory and peer-reviewed scientific sources.


Evidence for use in Erectile Dysfunction (ED)

Research has been conducted for Gramax in Erectile Dysfunction (ED), including multiple short-term, randomized, double-blind, placebo-controlled trials. Researchers primarily monitored patient-reported outcomes and functional ability, often using standardized questionnaires to assess changes in sexual function. Objective measurements of erection duration and hardness were assessed in some study participants. Findings describe patterns observed in the studies where short-term trials reported differences in these outcomes between the Gramax and placebo groups.

However, the majority of the original pivotal trials primarily focused on research exploring short-term symptom changes (typically 12 to 16 weeks). Long-term effects are not fully established within the controlled trial setting. Results apply only to the populations studied, and data for certain severe or specific underlying causes of ED may be drawn from smaller populations, meaning subgroup findings are uncertain in these instances.


Evidence for use in Pulmonary Arterial Hypertension (PAH)

For Pulmonary Arterial Hypertension (PAH), Gramax was studied in specific clinical trials focusing on outcomes related to physiological strain or activity level. The key measure used in research exploring how symptoms change over time was functional capacity, assessed by monitoring the 6-Minute Walk Distance (6MWD). Short-term trials in adults reported differences in functional capacity measurements when comparing the Gramax group to placebo groups, and follow-up research monitored patterns related to clinical worsening events.

What remains uncertain for this indication relates primarily to long-term data. The evidence base for children is complex: some low-dose data were examined regarding short-term functional changes, but follow-up data from a long-term extension study was subject to different safety interpretations by global regulatory bodies regarding high-dose use. This divergence indicates that long-term effects are not fully established for chronic outcomes in the pediatric group, and data for certain groups remain insufficient.


Research Gaps and Areas of Uncertainty

The research landscape highlights several key limitations. There is limited information for long-term outcomes in controlled settings for both PAH and ED. The most significant area of regulatory uncertainty involves the research for Gramax in children with PAH, where the long-term data was subject to differing interpretations, creating a research gap that requires further study. In general, few controlled trials have been published comparing Gramax against other available treatments in structured, head-to-head long-term settings. Research is ongoing to address these evidence gaps.

Frequently Asked Questions (FAQ)

Common questions about Gramax (FAQ)


Q: Is Gramax a narcotic or a controlled substance?

Official regulatory documents confirm that Sildenafil Citrate, the active ingredient in Gramax, is not classified as a narcotic. It is also not listed as a federally controlled substance by agencies such as the U.S. Drug Enforcement Administration (DEA).


Q: What is Gramax approved for by the FDA or other agencies?

Gramax is approved by the FDA for two primary indications. It is indicated for the treatment of Erectile Dysfunction (ED). It is also approved for treating Pulmonary Arterial Hypertension (PAH), which is intended to improve exercise capacity and delay disease progression.


Q: Does Gramax work right away, or does it take time to notice the effects?

Official information indicates that Gramax is rapidly absorbed after oral dosing. Maximum concentrations in the blood are typically reached within 30 to 120 minutes, with the median time being one hour when taken on an empty stomach. The onset of pharmacological activity for the medication is typically studied within a window of 30 minutes to four hours after administration.


Q: Is Gramax the same type of medicine as [similar generic drug name]?

Gramax is the brand name for the active ingredient Sildenafil Citrate. This substance belongs to the pharmacological class of Phosphodiesterase Type 5 (PDE5) Inhibitors. This classification defines the way the medicine works in the body by targeting a specific enzyme.


Q: Is it okay to cut or crush Gramax tablets?

Regulatory product information typically specifies the appropriate physical handling of the tablet, such as whether it can be cut or crushed. It is important that instructions regarding the physical modification of the tablet are reviewed within the specific prescribing information for Gramax.


Q: What happens if I miss a scheduled dose of Gramax?

Regulatory patient counseling generally includes guidance stating that a missed dose may be taken as soon as the patient remembers. However, if it is nearly time for the next scheduled dose, the official guidance often recommends skipping the missed dose.


Q: Do side effects from Gramax usually go away after a while?

In clinical trials, the adverse reactions reported were generally described as mild to moderate. Official data also indicates that these side effects were typically transient, meaning they did not last for a long duration.


Q: Can Gramax cause sleepiness or drowsiness?

The official product label does not list sleepiness or drowsiness among the very common or common adverse reactions. However, commonly reported effects include dizziness and insomnia (difficulty sleeping).


Q: Is it safe to drive or operate machinery while taking Gramax?

Because the medicine may cause adverse effects like dizziness and changes in vision, official patient counseling warns that Gramax may cause impairment. Due to the potential for impairment, patients are typically cautioned against driving or operating complex machinery until they understand the full effect the medicine has on them.


Q: Are there specific foods I should avoid while on Gramax?

Regulatory information highlights a potential interaction with the regular consumption of grapefruit or grapefruit juice. These products can potentially interfere with how the body metabolizes Gramax, which might lead to increased drug levels in the bloodstream or delay the onset of the medication’s effect.


Q: What common over-the-counter medicines interact with Gramax?

The official drug label highlights concerns for co-administration with certain Vitamin K antagonists (a type of blood thinner) due to an increased risk of nosebleeds. While the label does not specify all over-the-counter medicines, regulatory guidelines require that all medications and supplements are disclosed to the healthcare provider.


Q: Can I take Gramax if I drink alcohol?

Official information does not indicate a direct drug-alcohol interaction when consuming small amounts. As both Gramax and alcohol can independently influence blood pressure, official warnings note that consuming excessive alcohol may contribute to an increased likelihood of side effects like dizziness or headache.


Q: Is Gramax safe for older adults (seniors)?

Official documents address use in older adults (aged 65 years and over). Due to changes in how the body processes the medicine with age, a lower starting dose is often recommended for this population. This is a measure intended to help manage drug levels and potential side effects.


Q: Is Gramax a long-term or a short-term treatment?

The intended duration of use depends on the approved indication. Gramax prescribed for Erectile Dysfunction (ED) is taken as needed, making it a short-term use. For Pulmonary Arterial Hypertension (PAH), the medicine is taken on a fixed schedule and may be used as a chronic treatment.


Q: Does taking Gramax affect fertility in men or women?

Non-clinical studies conducted in animals did not show an effect on fertility from taking Sildenafil. However, regulatory documents state that data regarding the effect of Gramax on human fertility are not fully established or specifically detailed in the official product information.


Q: What should I do if I think I'm having an allergic reaction to Gramax?

Official warnings state that if signs of a severe allergic reaction are observed, such as swelling of the face, lips, or tongue, immediate cessation of Gramax is required. For any serious adverse event, including sudden vision or hearing loss, it is required that patients seek immediate medical attention.


Q: How does Gramax affect the liver or kidneys?

Official pharmacology information indicates that the body's processing of Gramax may be altered in patients who have severe impairment of the liver or kidneys. This can result in increased levels of the drug in the bloodstream. Consequently, a lower initial dose may be considered when prescribing the drug for these patient populations.


Q: Is there a generic version of Gramax available?

Yes, the active ingredient contained within Gramax, which is Sildenafil Citrate, has been made available as a generic medicine.


Q: What is the typical time frame for clinical improvement with Gramax?

The time frame for assessing changes depends on the condition being treated. For the acute effect in Erectile Dysfunction, efficacy was assessed approximately 60 minutes after taking the medicine. For Pulmonary Arterial Hypertension (PAH), clinical trials assessing improvement in exercise ability were typically conducted over a period of 12 to 16 weeks.


Q: Does Gramax interact with herbal supplements like St. John's Wort?

Regulatory documents show that Gramax is metabolized by certain enzymes in the body, specifically CYP3A4. While official drug labels may not list every herbal product, regulatory guidelines require that all herbal supplements are disclosed to the healthcare provider, as some may influence how the drug works or is cleared from the body.


Q: Is it normal to feel a certain way when first starting Gramax?

When first starting the medicine, it is possible to experience effects that are known to be common side effects of Gramax. These frequently reported effects from clinical trials include headache, flushing, and dizziness.


Q: Does Gramax have a Risk Evaluation and Mitigation Strategy (REMS) program?

The FDA maintains a registry for drugs that require a Risk Evaluation and Mitigation Strategy (REMS). Official information indicates that Gramax (Sildenafil Citrate) is currently not required by the FDA to have a REMS program in place.


Q: How long does Gramax stay in your system after the last dose?

According to the pharmacokinetics data, the half-life of Sildenafil is approximately 4 hours. This time frame represents how long it takes for half of the drug to be eliminated from the bloodstream. It is generally cleared from the body within 20 hours following the last dose.


Q: Does Gramax have a Black Box Warning?

The official prescribing information published by the FDA does not contain a Black Box Warning. This type of warning is the most serious form of warning that the agency requires to be placed on a drug label.


Q: Can I use Gramax if I have glaucoma or other eye conditions?

Official warnings concern sudden visual loss due to conditions like Non-arteritic Anterior Ischemic Optic Neuropathy (NAION). The drug is generally not recommended for patients who have a history of NAION or a rare inherited eye condition called retinitis pigmentosa. Glaucoma itself is not explicitly listed as a contraindication in the official documents.


Q: Does Gramax interact with vitamins or minerals?

The official label notes a concern for co-administration with Vitamin K antagonists (a medication used as a blood thinner) because of a higher risk of nosebleeds. Regulatory guidelines emphasize the need for patients to fully inform their prescriber about all vitamins and minerals they are taking.


Q: What are the demographics of the patient population studied in Gramax trials?

Clinical trial populations included adult men with Erectile Dysfunction and adult patients with Pulmonary Arterial Hypertension (PAH), many of whom had specific classifications like NYHA Functional Class II-III. Research has also been conducted involving pediatric patients with PAH.


Q: Can Gramax cause skin rashes or sensitivity to the sun?

Mild side effects reported in clinical trials include skin rash and erythema (reddening of the skin). However, official product information does not generally list sensitivity to the sun (photosensitivity) as a reported adverse reaction.


Q: What should I do in the event of an overdose of Gramax?

Official guidance states that immediate contact with emergency services or the treating doctor is required in the event of an overdose. Clinical studies involving high single doses of the medicine reported that the resulting adverse events were similar to those at lower doses, but with observed increases in both the rate and severity of the effects.


Q: Why is Gramax sometimes prescribed with other medications?

For the treatment of Pulmonary Arterial Hypertension (PAH), regulatory documents confirm that Gramax has been studied for use in combination with other therapies. For example, it has been approved for use when added to background epoprostenol therapy to support improvements in exercise capacity.


How should Gramax be stored and disposed of?

How to Store and Dispose of Gramax

Gramax (Sildenafil Citrate) tablets must be stored according to official regulatory specifications to maintain product stability and integrity.


Storage Requirements

Condition Regulatory Requirement
Temperature Store at controlled room temperature (e.g., below 30 C).
Protection Must be kept in the original container to protect from moisture and light.
Handling The product should not be refrigerated or frozen.
Child Safety Store securely, out of the sight and reach of children.

Storage conditions are standardized to require controlled room temperature and protection from environmental factors, necessitating the product remain in its original packaging.


Disposal Instructions

Unused or expired Gramax must be disposed of according to local regulations or via an approved drug take-back program. It is officially mandated not to dispose of the medicine in wastewater (do not flush or pour down the sink).

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Gramax found in:

A-Z Index: